Introduction {#S1}
============

Onconeural antibody-associated disorders (OAADs) are a type of heteroplasmic neurological syndrome and are drawing increasing attention from neurologists. OAADs are usually associated with some form of neuronal autoantibody, part of which is known to be associated with systemic cancer. The target antigens include nuclear or cytoplasmic proteins, such as Hu, Yo, Ri, or intracellular synaptic proteins, such as 65 kDa glutamic acid decarboxylase, amphiphysin, or cell-surface or synaptic proteins, such as the *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR), the α-amino-3-hydroxy-5 -methyl-4-isoxazolepropionic acid receptor, and the γ-aminobutyric acid receptor-B (GABABR) ([@B1]--[@B3]). Furthermore, OAADs can be broadly divided into two clinical categories: classic paraneoplastic neurological syndromes (PNDs) and autoimmune encephalitis (AE) ([@B4]).

Paraneoplastic neurological disorders are mostly accepted as neurological syndromes that are immune mediated and triggered when systemic tumors express certain neuronal antigens ([@B3]). PND syndromes can manifest in the central nervous system, peripheral system, neuromuscular junction and muscle ([@B5]). However, AE generally refers to a group of disease processes that share analogical clinical features and neuroimaging findings and are largely differentiated by characteristic antibodies which mediate immune attacks on different neural structures ([@B6]). The presentations of AE include memory or behavioral deficits, new focal findings, seizures, cerebrospinal fluid (CSF) pleocytosis, and abnormalities upon magnetic resonance imaging (MRI) ([@B7]). Previous reports have indicated that approximately 1 in 10,000 patients with cancer eventually develop PNDs ([@B8]), thus showing that this disease is associated with a low prevalence. In other research, patients were preselected using clinical criteria and serological screening; these data showed that 163/649 (25%) cases were serologically positive for antibodies associated with PNDs during a 23-month period ([@B4]). In terms of AE, the annual incidence of encephalitis, of any etiology, is 2--3 cases per 100,000 patients in northern Europe ([@B9]), of which, at least 20% are immune mediated. The predominant cohort of patients for AE includes those with anti-NMDA-receptor encephalitis (4%) and voltage-gated potassium channels (VGKC)-complex antibody positive encephalitis (3%) ([@B9]).

In the present study, we analyzed the medical records from a series of patients with OAAD, investigated the spectrum of clinical characteristics and management strategies associated with this disease and evaluated potential predictors which could be used to influence outcome.

Materials and Methods {#S2}
=====================

Standard Protocol Approvals and Patient Consent {#S2-1}
-----------------------------------------------

The study was approved by the ethics committee of the General Hospital of Jinan Military Command (NO. 201611). All patients provided informed written consent to allow their medical records to be used in this study. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki.

Study Design {#S2-2}
------------

We conducted a retrospective review of all patients with potential PNDs or AE between September 2009 and July 2017, and who were tested for classical paraneoplastic antibodies and autoimmune synaptic antibodies. Records were manually reviewed and patients with a final diagnosis of PNDs, AE, or possible OAAD were recruited into this study.

Definitions Used in This Study {#S2-3}
------------------------------

We used specific diagnostic criteria to define PNDs and AE ([@B5]). Definite PNDs were defined as follows: (1) a classical syndrome and cancer that develops within 5 years of the diagnosis of neurological disorder; (2) a non-classical syndrome that resolves or significantly improves after cancer treatment without concomitant immunotherapy, provided that the syndrome was not susceptible to spontaneous remission; (3) a non-classical syndrome with onconeural antibodies (well characterized or not) and cancer that develops within 5 years of the diagnosis of neurological disorder; (4) A neurological syndrome (classical or not) with well characterized onconeural antibodies (anti-Hu, Yo, CV2, Ri, Ma2, or amphiphysin), but without cancer. Possible PNDs were defined as described previously ([@B5]): (1) a classical syndrome, no onconeural antibodies, no cancer but at high risk of an underlying tumor; (2) a neurological syndrome (classical or not) with partially characterized onconeural antibodies but without cancer; and (3) a non-classical syndrome, no onconeural antibodies, and the presence of cancer within 2 years of diagnosis.

Definite AE was defined, as described previously ([@B7]): (1) sub-acute onset (rapid progression of less than 3 months) of working memory deficits (short-term memory loss), altered mental status, or psychiatric symptoms; (2) at least one of the following: new focal CNS findings; seizures which could not be explained by a previously known seizure disorder; CSF pleocytosis (white blood cell count of more than five cells per mm^3^); MRI features suggestive of encephalitis; (3) positive antibody testing in the serum or CSF, mainly targeting cell-surface or synaptic proteins; and (4) reasonable exclusion of other disorders. Possible AE was defined as an absence of positive antibody testing in the serum or CSF.

The "duration prior to the hospital" was defined as the number of days from the onset of symptoms to hospitalization in our hospital. A "good outcome" was defined as a grade of 0--2 on the modified Rankin Scale (mRS), while a "poor outcome" was defined as a mRS of 3--6. An "immunocompromised state" was defined as when patients received chemotherapy, chronic immunosuppressants or steroids (for \>3 months). IgG index was calculated according to the following formula: \[CSF IgG (mg/mL)/serum IgG (mg/mL)\]/\[CSF albumin (mg/mL)/serum albumin (mg/mL)\]. MRI fluid-attenuated inversion recovery (FLAIR)/T2 abnormality was defined as high signal intensity in images of the brain parenchyma. "Total tumors" refers to the total number of tumors for a specific patient, including those which were newly identified, and those recorded in historical records.

Inclusion/Exclusion Criteria {#S2-4}
----------------------------

Patients were included in the study if they concurred with criteria outlined above, and were under treatment in our hospital. We excluded cases if there was any evidence of infectious or post-infectious encephalitis, autoimmune disease-associated encephalitis, toxic-metabolic encephalopathy, brain tumor or metastasis, vitamin deficiency or alcohol-related encephalopathy, side-effects of drugs (chemotherapeutics or others), primary angiitis of the CNS, or other diseases (e.g., acquired immune deficiency syndrome and Creutzfeldt--Jakob disease).

Categorization of Patients {#S2-5}
--------------------------

Patients were categorized into three groups: those with PNDs, AE, or possible OAAD. Patients were categorized as definite PNDs or AE when they concurred with the appropriate definitions. Patients who were classified as possible PNDs or AE were all categorized into the possible OAAD group.

Clinical Characteristics and Investigations {#S2-6}
-------------------------------------------

Basic demographic information (age, gender) were collated for each patient, along with the duration prior to the hospital, and whether there was an immunocompromised state or not. All patients underwent consultation and a neurological examination by an attending neurologist, who ascertained clinical symptoms, neurological signs, and mRS upon admission. The same information was collected just prior to discharge. mRS data were collected by telephone follow-up on a semi-annual basis. During the period of hospital care, intensive care unit (ICU) admission, mechanical ventilation, and therapy were recorded.

In this study, we analyzed a range of laboratory data, including CSF analysis (glucose, protein, white blood cells, IgG index), serum autoantibodies \[anti-nuclear antibodies (ANA), onconeural antibodies\] and tumor markers \[neuron-specific endase (NSE), carcinoembryonic antigen (CEA)\]. Data were also acquired so that we could evaluate the function of crucial organs, such as the heart, liver, and kidney and also the relative state of hemopoiesis. Such data included creatine phosphokinase isoenzyme (CK-MB), glutamic oxalacetic transaminase/glutamic-pyruvic transaminase (AST/ALT), urea nitrogen/creatinine (BUN/Cr), the counts of leukocyte, polymorphonuclear and thrombocyte. Electroencephalograms (EEGs) and electromyography (EMG) were also carried out in order to assess electrophysiology. Neuroimaging examinations, including brain MRI FLAIR/T2 abnormality and computed tomography (CT), were also used to investigate for underlying tumors. All of the results were studied from the first time in our hospital.

Statistics {#S2-7}
----------

The data were analyzed using Excel 2016. Normality was assessed using the Shapiro--Wilk Normality Test on R software. Continuous variables, which were normally distributed, were compared between groups with the Student's *t*-test. For continuous variables that did not follow normal distributions, we used the Mann--Whitney *U* test (Wilcoxon rank-sum test). The Chi-square test or Fisher's exact test, as appropriate, was used to compare categorical variables between groups, and a binomial logistic regression model was used to evaluate the association between variables and outcome. All statistical analyses were performed in R (the R Project: <http://www.R-project.org>). Odds ratios (ORs) and their 95% confidence intervals (CIs) were also calculated. The predefined level of significance was 0.05.

Results {#S3}
=======

Demographics and Clinical Characteristics {#S3-1}
-----------------------------------------

From a total of 158 patients, we identified 70 patients who fulfilled the criteria for OAAD, including 44 men (62.9%) and 26 women (37.1%) with a median age of 55 years (range: 14--78 years). The median duration prior to the hospital was 74 (range: 7--1,090). The median number of days in hospital was 37 (range: 3--116). A summary of the patient demographics and characteristics is given in Table [1](#T1){ref-type="table"}.

###### 

Demographics, clinical presentation, management, and outcome.

  Age, sex   Diagnosis                                                                    Clinical presentation                                              Types of onset        Onconeural antibody                                         Associated tumor                                Tumor marker               Coexistent autoantibody         Modified Rankin Scale (mRS) on admission   Therapy                                   Hospital stay   mRS final
  ---------- ---------------------------------------------------------------------------- ------------------------------------------------------------------ --------------------- ----------------------------------------------------------- ----------------------------------------------- -------------------------- ------------------------------- ------------------------------------------ ----------------------------------------- --------------- -----------
  31, M      Anti-NMDAR encephalitis                                                      Double vision                                                      Chronic               *N*-methyl-[d]{.smallcaps}-aspartate receptor (NMDAR), Ta                                                                              Anti-AQP4, anti-MPO, anti-PR3   3                                          Steroids                                  37              2
  55, F      Limbic encephalitis                                                          Mental and behavior disorder, cognitive damage, epilepsy           Sub-acute             Amphiphysin                                                 Lung cancer                                     NSE, CA125                                                 5                                          steroids, IVIg                            17              5
  61, F      Peripheral neuropathy                                                        Extremities numbness and weakness                                  Sub-acute             Hu                                                          Breast cancer, malignant fibrous histiocytoma                                                              4                                                                                    9               3
  37, M      Peripheral neuropathy                                                        Extremities numbness                                               Chronic               Hu                                                          Lung cancer                                     NSE, CEA                                                   2                                                                                    10              2
  17, M      Paraneoplastic cerebellar degeneration                                       Limb seizures                                                      Chronic               SOX1                                                                                                                                                                   3                                                                                    11              3
  56, F      Anti-NMDAR encephalitis                                                      Hypomnesis, mental and behavior disorder, confusion                Acute                 NMDAR                                                       Small cell lung cancer (SCLC)                                                                              5                                          Steroids, IVIg                            47              6
  62, F      Peripheral neuropathy                                                        Weakness of limbs                                                  Chronic               CV2, Hu                                                     Lung cancer                                     NSE, CEA, CA125, CA199                                     3                                                                                    7               3
  66, M      Paraneoplastic cerebellar degeneration                                       Barylalia, walk unsteadily                                         Sub-acute             CV2                                                                                                                                    ANA                             2                                                                                    17              2
  46, F      Encephalomyelitis                                                            Weakness of limbs                                                  Chronic               Yo                                                          Breast cancer, multiple myeloma                                                                            2                                          IVIg                                      17              6
  48, F      Peripheral neuropathy                                                        Extremities numbness and weakness                                  Chronic               Yo                                                                                                                                                                     3                                                                                    8               6
  35, M      Anti-NMDAR encephalitis                                                      Mental and behavior disorder                                       Acute                 NMDAR                                                                                                                                  Anti-nuclear, anti-M2           3                                          IVIg, steroids                            38              0
  72, M      Peripheral neuropathy                                                        Lower limbs weakness                                               Chronic                                                                           Squamonus cell carcinoma of lung                NSE                                                        3                                                                                    53              6
  54, M      Paraneoplastic cerebellar degeneration                                       Dysarthria, walk unsteadily                                        Chronic               Ri                                                          Colon cancer                                                                                               4                                          Colon surgery                             8               4
  60, M      Peripheral neuropathy                                                        Waist pain, ache of right lower limb                               Sub-acute                                                                         Multiple myeloma                                                                                           4                                          IVIg, chemotherapy, steroids              116             5
  66, M      Gabab encephalitis                                                           Epilepsy, right hemidysesthesia, lower limbs weakness              Chronic               GABAb                                                                                                                                                                  3                                          IVIg                                      11              2
  54, F      Anti-NMDAR encephalitis                                                      unresponsive, mental and behavior disorder                         Acute                 NMDAR                                                                                                                                                                  3                                          IVIg, steroids                            14              2
  54, M      Limbic encephalitis                                                          Hypomnesis, unresponsive, epilepsy                                 Sub-acute                                                                                                                         AFP                                                        4                                          IVIg                                      15              1
  24, F      Anti-NMDAR encephalitis                                                      Headache, hallucination, epilepsy                                  Acute                 NMDAR                                                                                                       CA125                                                      5                                          IVIg                                      55              0
  52, F      Paraneoplastic cerebellar degeneration                                       Dizziness, walk unsteadily, nausea and vomit                       Sub-acute             Hu                                                          SCLC                                            CEA, CA125                                                 4                                          Lung cancer resection                     42              2
  22, M      Necrotizing myopathy                                                         Weakness of limbs                                                  Sub-acute             Yo                                                                                                          NSE                        Anti-Jo1, anti-Mi2, anti-SRP    3                                          Steroids                                  23              2
  70, M      Limbic encephalitis                                                          Epilepsy                                                           Acute                                                                             Rectal cancer                                   NSE                        ANA                             2                                          Steroids, IVIg                            47              1
  76, M      Myasthenic syndrome                                                          Lower limbs weakness                                               Chronic               Ta                                                          SCLC                                            CEA, CA199, CY211                                          2                                                                                    5               1
  27, M      Anti-NMDAR encephalitis                                                      Fever, epilepsy                                                    Sub-acute             NMDAR                                                                                                       NSE                                                        5                                          Plasma exchange, cyclophosphamide, IVIg   71              4
  76, F      Brainstem encephalitis                                                       Weakness of limbs, dysphagia                                       Sub-acute             Hu                                                                                                          CEA, CA125, CY211                                          5                                          IVIg, steroids                            79              6
  65, M      Lambert--Eaton myasthenic syndrome                                           Weakness of limbs                                                  Sub-acute             Yo                                                          Adenocarcinoma of anal canal                                               Anti-VGCC                       4                                          IVIg, excision of anal canal carcinoma    13              3
  37, M      Anti-NMDAR encephalitis                                                      cognitive decline                                                  Chronic               NMDAR                                                                                                       AFP                                                        4                                          IVIg                                      4               3
  74, F      Motor neuron disease, limbic encephalitis                                    Barylalia, bucking                                                 Chronic               Yo                                                                                                          NSE                                                        3                                                                                    4               6
  62, M      Peripheral neuropathy                                                        Extremities numbness and weakness                                  Chronic               Hu                                                                                                          CEA                        Anti-SSA, anti-Ro52, anti-HI    4                                          IVIg, steroids                            8               6
  72, M      Guillain--Barre syndrome                                                     Extremities numbness and weakness, hoarseness                      Acute                 Yo                                                                                                          NSE, CEA                                                   2                                                                                    3               0
  14, F      Anti-NMDAR encephalitis                                                      Mental and behavior disorder, epilepsy                             Acute                 NMDAR                                                                                                                                  ANA                             3                                                                                    21              0
  41, M      Anti-NMDAR encephalitis                                                      Mental and behavior disorder                                       Acute                 NMDAR                                                                                                                                                                  3                                          IVIg                                      35              1
  43, F      Myasthenia gravis                                                            Blepharoptosis, barylalia, dysphagia                               Sub-acute             Titin                                                                                                                                  Anti-GM1, anti-AchR             2                                                                                    6               1
  56, F      Limbic encephalitis                                                          Mental and behavior disorder                                       Chronic               Hu                                                                                                                                                                     4                                                                                    7               3
  40, F      Anti-NMDAR encephalitis                                                      Mental and behavior disorder                                       Acute                 NMDAR                                                                                                                                                                  3                                          Steroids, IVIg                            16              1
  64, M      Lambert--Eaton myasthenic syndrome                                           Weakness of limbs                                                  Chronic                                                                           SCLC                                                                                                       3                                                                                    8               3
  52, M      Lambert--Eaton myasthenic syndrome                                           Lower limbs weakness                                               Chronic                                                                           Thymoma                                                                                                    1                                                                                    7               1
  71, M      Peripheral neuropathy+paraneoplastic cerebellar degeneration                 Lower limbs weakness                                               Chronic               Ri                                                          SCLC                                                                                                       3                                                                                    6               2
  63, F      Limbic encephalitis                                                          Headache, mental and behavior disorder, epilepsy                   Acute                                                                                                                                                                                        5                                          IVIg                                      16              0
  60, M      Chronic Guillain--Barre syndrome                                             Extremities numbness and weakness                                  Chronic progressive   Ta                                                                                                          CY211                      Anti-GM3, anti-GT1b             3                                          Steroids                                  20              0
  70, F      Limbic encephalitis                                                          Lower limbs weakness, aconuresis, Hypomnesis, personality change   Chronic               Hu                                                          SCLC                                            NSE                                                        4                                                                                    13              3
  78, M      Myasthenia gravis                                                            Gatism                                                             Chronic               Hu                                                          Lung cancer                                     NSE, CA199, CA724, CY211                                   3                                                                                    7               3
  42, M      Paraneoplastic cerebellar degeneration                                       Walk unsteadily, involuntary movement                              Sub-acute                                                                         SCLC                                                                       Anti-CB                         4                                          IVIg, cyclophosphamide                    40              4
  37, M      Lambert--Eaton myasthenic syndrome                                           Limb weakness, emaciation                                          Chronic                                                                                                                                                                                      1                                                                                    7               1
  54, M      Myelitis                                                                     Numbness and weakness of the lower limbs                           Sub-acute             Hu                                                          Squamous cell lung carcinoma                    NSE, CY211                                                 5                                                                                    11              5
  66, F      Motor neuron disease                                                         Labored breathing, hoarseness                                      Chronic               Hu                                                          Ovary tumor                                                                Anti-AchR                       2                                                                                    5               3
  29, F      Paraneoplastic cerebellar degeneration                                       Walk unsteadily, barylalia                                         Chronic               Yo                                                          Breast infiltrating ductal carcinoma                                                                       2                                                                                    37              2
  56, M      Brainstem encephalitis                                                       Barylalia, lower limbs weakness                                    Acute                 Amphiphysin                                                 SCLC                                                                                                       4                                          Chemotherapy                              16              2
  49, M      Vasculitic peripheral neuropathy                                             Myalgia of the upper legs, intermittent fever                      Chronic               Ta                                                                                                          CY211                      Anti-Ro52, anti-MPO             3                                          IVIg, cyclophosphamide                    18              2
  24, M      Myelitis                                                                     Progressive numbness of lower limbs                                Sub-acute             Yo                                                                                                                                                                     1                                          Steroids                                  3               1
  54, M      Peripheral neuropathy                                                        Lameness, weakness of the toes                                     Chronic               CV2                                                         Renal carcinoma                                                                                            2                                                                                    9               3
  56, M      Motor neuron disease                                                         Weakness of limbs, dysphagia                                       Chronic                                                                           Lung cancer                                     NSE, CY211                                                 3                                                                                    7               2
  57, M      Lambert--Eaton myasthenic syndrome                                           Lower limbs weakness, paroxysmal unconsciousness                   Chronic                                                                           SCLC                                                                       ANA                             3                                          Steroids, IVIg                            11              2
  41, M      Anti-NMDAR encephalitis                                                      Mental and behavior disorder, epilepsy                             Acute                 NMDAR                                                       Intracranial tumor                              NSE                        Anti-SSA, anti-Ro52             5                                          IVIg                                      90              5
  57, F      Paraneoplastic cerebellar degeneration                                       Dizziness, walk unsteadily                                         Acute                                                                             Lung cancer                                     NSE                                                        4                                                                                    10              4
  65, F      Myelitis                                                                     Numbness and weakness of right lower limb                          Sub-acute                                                                         Ovarian cancer                                  CA199                      Anti-AQP4                       4                                          Steroids                                  10              6
  49, M      Autoimmune encephalitis                                                      Involuntary movement of limbs, unconsciousness                     Acute                                                                                                                                                                                        2                                          IVIg, steroids                            5               1
  63, M      Paraneoplastic cerebellar degeneration                                       Barylalia, walk unsteadily                                         Sub-acute                                                                         Bladder cancer                                                                                             3                                          Steroids                                  14              2
  49, M      Anti-NMDAR encephalitis                                                      Headache                                                           Acute                 NMDAR                                                       Adrenal gland neoplasms                                                                                    1                                          IVIg                                      46              6
  65, F      Peripheral neuropathy                                                        Progressive numbness and weakness of limbs, bathesthesia           Chronic               Hu                                                                                                                                     Anti-GM                         2                                                                                    13              5
  28, M      Motor neuron disease                                                         Weakness of the upper limbs                                        Chronic               Yo                                                                                                                                                                     2                                                                                    10              2
  77, M      Limbic encephalitis                                                          Mental and behavior disorder                                       Chronic                                                                                                                                                                                      4                                          Steroids, IVIg                            9               1
  49, M      Paraneoplastic cerebellar degeneration, Lambert--Eaton myasthenic syndrome   Dizziness, walk unsteadily                                         Chronic                                                                           SCLC                                            NSE                                                        3                                          Steroids                                  9               3
  60, M      Lambert--Eaton myasthenic syndrome, paraneoplastic cerebellar degeneration   Weakness of limbs                                                  Chronic                                                                                                                                                      Anti-Scl70, ANA                 4                                          Steroids                                  7               6
  44, F      Paraneoplastic cerebellar degeneration                                       Headache, dizziness, walk unsteadily                               Chronic               YO                                                                                                                                                                     4                                                                                    6               3
  55, M      Lambert--Eaton myasthenic syndrome                                           Lower limbs weakness                                               Acute                                                                             Lung adenocarcinoma                                                                                        2                                          Lung cancer resection                     21              2
  61, F      Peripheral neuropathy                                                        Weakness of both hands                                             Chronic               Hu                                                                                                                                                                     4                                                                                    14              2
  70, F      Anti-NMDAR encephalitis                                                      Increases in sleep, lower limbs weakness                           Sub-acute             NMDAR                                                       Ovarian teratoma                                                                                           3                                          Steroids, IVIg                            27              2
  40, F      Encephalomyelitis                                                            Lower limbs weakness, hypopsia                                     Chronic               Am                                                          Breast infiltrating ductal carcinoma                                                                       4                                                                                    11              4
  43, M      Myelitis                                                                     Pain of right waist, numbness and weakness of lower limbs          Chronic               Ta                                                                                                                                                                     3                                          Steroids, azathioprine                    21              3
  69, M      Motor neuron disease                                                         Barylalia, dysphagia, weakness of the upper limbs                  Chronic               Yo                                                                                                                                                                     3                                                                                    7               6

*NSE, Neuron-specific endase; AFP, alpha fetoprotein; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; CY, cytokeratin; AQP, Aquaporin; MPO, myeloperoxidase; PR, protease; ANA, anti-nuclear antibodies; M2, mitochondrion 2; Jo1, histidyl tRNA synthase 1; Mi2, 218/240 kDa helicase family protein; SRP, signal recognition particle; VGCC, Calcium ion channel antibody; SSA, Sjogren syndrome A; Ro -52, 52k Da Sjogren syndrome A; HI, histone; GM, gangliosides; AchR, acetylcholine receptors; GT1b, trisialic acid ganglion; CB, centromere protein B; Scl, scleroderma; IVIg, intravenous immunoglobulin*.

In this study, 38 patients (54.3%) were classified into the PNDs group, including 17 women (44.7%) and 21 men (55.3%). There were 14 patients (20%) diagnosed with AE, including 6 women (42.9%) and 8 men (57.1%). The other 18 patients (25.7%) were classified as having possible OAAD, including 3 women (16.7%) and 15 men (83.3%). There were 17 patients (24.3%) with mental and behavioral abnormalities, 13 (18.6%) with epilepsy, and 12 (17.1%) with autonomic neuropathic lesions. Detailed statistical analysis of patient demographics, clinical presentation, and hospital course, in each of the three groups, is given in Table [2](#T2){ref-type="table"}.

###### 

Demographics, clinical presentation, and management.

                                             Paraneoplastic neurological disorders (*n* = 38)   Autoimmune encephalitis (*n* = 14)   Possible onconeural antibody associated disorders (*n* = 18)
  ------------------------------------------ -------------------------------------------------- ------------------------------------ --------------------------------------------------------------
  Age, year                                  55.5 (22--78)                                      40.5 (14--70)                        60 (17--77)
  Male                                       21 (55.3%)                                         8 (57.1%)                            15 (83.3%)
  **Before hospitalization**                                                                                                         
  Immunocompromised state                    9 (23.7%)                                          3 (21.4%)                            5 (27.8%)
  Duration prior to the hospital, days       120 (15--1,090)                                    22.5 (8--365)                        60 (7--365)
  **Clinical presentation**                                                                                                          
  Cognition damage                           4 (10.5%)                                          10 (71.4%)                           3 (16.7%)
  Psychological and behavioral abnormality   4 (10.5%)                                          10 (71.4%)                           3 (16.7%)
  Confusion                                  1 (2.6%)                                           5 (35.7%)                            1 (5.6%)
  Epilepsy                                   2 (5.3%)                                           7 (50%)                              4 (22.2%)
  Focal deficits                             21 (55.3%)                                         1 (7.1%)                             8 (44.4%)
  Urinary incontinence/retention             6 (15.8%)                                          3 (21.4%)                            3 (16.7%)
  **During hospitalization**                                                                                                         
  Temperature upon admission, °C             36.5 (35.9--37.1)                                  36.55 (36.2--39)                     36.4 (36--37.8)
  ICU admission                              1 (2.6%)                                           4 (28.6%)                            1 (5.6%)
  Mechanical ventilation                     1 (2.6%)                                           4 (28.6%)                            0
  Immunotherapy                              11 (28.9%)                                         13 (92.9%)                           11 (61.1%)
  Total tumors                               23 (60.5%)                                         4 (28.6%)                            8 (44.4%)
  Hospital stay, d                           10 (3--79)                                         36 (4--90)                           10.5 (3--116)

*Data presented as *n* (%) or median (range)*.

*ICU, intensive care unit; WBC, white blood cell; ADA, adenosine deaminase; Glu, glucose; ALB, albumin; QALB, albumin quotient; TGAb, antithyroglobulin antibody; TPOAb, anti-thyroid peroxidase antibody; NSE, Neuron-specific endase; AFP, alpha fetoprotein; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; CY, cytokeratin; CK-MB, creatine phosphokinase isoenzyme; AST, glutamic oxalacetic transaminase; ALT, glutamic-pyruvic transaminase; BUN, urea nitrogen; Cr, creatinine; PMN, polymorphonuclear; EEG, electroencephalogram; EMG, electromyography; FLAIR, fluid-attenuated inversion recovery*.

Investigations {#S3-2}
--------------

During hospitalization, 60 patients (85.7%) underwent CNS examination by MRI and 18 patients (30%) were identified as having FLAIR/T2 abnormalities. Furthermore, 27 patients (38.6%) received EEG examinations, 19 of which (70.4%) showed an abnormal slow wave or a sharp and slow wave. EMG was performed in 41 patients (58.6%) and identified 37 positive cases (90.2%). Selected patients underwent CSF examination to determine cell count, protein concentration, and immunoglobulin (Ig) concentration. We also tested characterized onconeural antibodies (anti-Hu, Yo, Ri, Ma2, CV2, and amphiphysin) in 67 patients (95.7%) and NMDAR antibody in 27 patients (38.6%). A further cohort of 59 patients (84.3%) were screened for serum tumor markers, including NSE, AFP, CEA, CA125, CA153, CA199, CA724, and CY211; 26 positive cases (44.1%) were identified. Coexistent autoantibodies were also examined in 37 patients (54.3%), including anti-nuclear/myositis/ganglioside antibody profiles, anti-myeloperoxidase (MPO)/protease 3 (PR3)/acetylcholine receptors (AchR)/aquaporin 4 (AQP4) antibodies, and 19 patients (51.4%) were shown to exhibit the coexistence of other autoantibodies.

We also collected a range of other data to allow us to evaluate the status of primary organ function. All patients were tested for AST/ALT, BUN/Cr, the counts of leukocyte, polymorphonuclear, and thrombocyte, and CK-MB was tested in 44 patients (62.9%). The results were analyzed to identify potential predictors of outcome and are presented in Table [3](#T3){ref-type="table"}.

###### 

Cerebrospinal fluid (CSF), other test results, electrophysiology, and radiological findings.

                                                      Paraneoplastic neurological disorder   Autoimmune encephalitis    Possible
  --------------------------------------------------- -------------------------------------- -------------------------- --------------------------
  **CSF analysis**                                                                                                      
  WBC, ×10^6^/L                                       9.0 (9.0--60.0), 19                    10.5 (0.0--96.0), 12       2.0 (1.0--30.0), 12
  Protein, mg/L                                       0.5 (0.2--1.5), 18                     0.5 (0.2--0.9), 12         0.5 (0.2--3.9), 12
  Cl, mmol/L                                          122.2 (107.0--128.3), 17               124.5 (109.3--129.7), 12   121.1 (106.4--132.8), 12
  Glu, mmol/L                                         3.7 (2.5--5.2), 17                     3.4 (3.2--4.7), 12         3.6 (3.1--8.6), 12
  Qalb, ×1,000                                        7.6 (3.5--63.8), 11                    7.5 (2.6--16.1), 9         9.0 (2.2--70.0), 9
  IgG Index, ×1,000                                   593.3 (231.1--791.9), 7                548.0 (161.9--721.5), 5    503.7 (348.1--701.1), 5
  **Serum autoantibody and tumor markers**                                                                              
  TGAB, IU/mL                                         0.1 (0.0--38.7), 30                    0.2 (0.0--175.0), 10       1.5 (0.1--36.0), 10
  TPO, IU/mL                                          0.4 (0.1--39.7), 30                    0.7 (0.1--131.0), 10       1.7 (0.2--1,087.0), 10
  Other autoantibodies                                9 (50%), 18                            4 (44.4%), 9               6 (60%), 10
  Neuron-specific endase, μg/L                        14.0 (7.0--180.5), 27                  11.7 (8.6--30.1), 10       14.5 (9.1--47.9), 10
  AFP, ng/mL                                          2.9 (0.6--6.0), 28                     1.3 (0.6--8.5), 11         2.9 (1.5--10.3), 15
  Carcinoembryonic antigen, μg/L                      2.4 (0.5--13.1), 30                    2.3 (1.0--4.5), 11         1.7 (0.5--7.6), 15
  **Organic function evaluation**                                                                                       
  CK-MB, U/L                                          10.0 (4.0--341.0), 26                  13.0 (6.0--98.0), 9        11.0 (6.0--24.0), 9
  AST/ALT, ×100                                       110.4 (37.0--666.7), 38                127.7 (32.5--204.8), 14    117.4 (45.6--214.3), 9
  BUN/Cr, ×100                                        6.6 (3.0--13.2), 38                    7.5 (1.8--12.6), 14        6.5 (2.0--14.5), 18
  WBC, ×10^9^/L                                       6.1 (2.5--21.7), 38                    8.3 (5.3--18.4), 14        7.9 (3.9--11.9), 18
  PMN, %                                              65.8 (35.9--90.1), 38                  72.8 (58.5--92.7), 14      73.0 (43.7--94.5), 18
  Platelet, ×10^9^/L                                  229.5 (102.0--587.0), 38               223.0 (140.0--377.0), 14   232.5 (53.0--363.0), 18
  **Electrophysiology and radiological findings**                                                                       
  Electromyography                                    26 (96.3%), 27                         0                          8 (72.7%), 11
  Electroencephalogram                                4 (80%), 5                             11 (78.6%), 14             6 (75%), 8
  Magnetic resonance imaging FLAIR/T2 abnormalities   10 (33.3%), 30                         5 (35.7%), 14              3 (18.8%), 16
  Computed tomography finding on tumor                10 (35.7%), 28                         1 (8.3%), 12               2 (15.4%), 13

*Data presented as positive specimen (%) sample size, or median (range) sample size*.

Diagnosis and Treatment {#S3-3}
-----------------------

Patients included in this study were divided into three groups: those with PNDs (38 patients, 54.3%), AE (14 patients, 20%) and possible OAAD (18, 25.7%). The main diagnoses were anti-NMDAR encephalitis (13/70 patients, 18.6%), peripheral neuropathy (12/70 patients, 17.1%), paraneoplastic cerebellar degeneration (12/70 patients, 17.1%) and Lambert-Eaton myasthenic syndrome (8/70 patients, 11.4%). The main onconeural antibodies detected were anti-Hu (13/70 patients, 18.6%), anti-NMDAR (13/70 patients, 18.6%), and anti-Yo (11/70 patients, 15.7%). Overall, 36 patients (51.4%) were found to possess associated tumors, the most common tumor being lung cancer (19/36 patients, 52.8%), particularly small cell lung cancer (SCLC) (10/19 patients, 52.6%).

In total, 39 patients (55.7%) underwent anti-tumor or immunotherapy and 4 patients (10.3%) received tumor surgery, 22 patients (56.4%) were administered with steroids, 26 patients (66.7%) were treated with IVIg, and 13 patients (33.3%) received both steroids and IVIg. Some patients were admitted into the ICU (6/70 patients, 8.6%), and five patients (7.1%) required mechanical ventilation.

Outcomes {#S3-4}
--------

At discharge, there were 17 patients (44.7%) with PNDs, 9 (64.3%) with AE and 10 (55.6%) with possible OAAD who had a good outcome. By contrast, there were 21 (55.3%) patients with PNDs, 5 (35.7) with AE and 8 (44.4%) with possible OAAD who had a poor outcome. After the last follow-up (median: 23 months; range: 0--84), 14 patients (36.8%), 9 patients (64.2%), and 12 patients (66.7%) had a good outcome. However, six patients (15.8%), two patients (14.3%), and three patients (16.7%) died in the three cohorts, respectively.

Predictors of Outcome {#S3-5}
---------------------

After the last follow-up, the entire patient cohort was classified into groups of good (mRS = 0--2) or poor (mRS = 3--6) outcome after the last follow-up. Univariate analysis was then used to assess variables which were potentially associated with the functional outcome of patients (Table [4](#T4){ref-type="table"}). Univariate analysis showed that duration prior to the hospital (*p* = 0.0224) and urinary incontinence/retention (*p* = 0.0043) were factors associated with poor outcome.

###### 

Variables associated with functional outcome in onconeural antibody associated disorders patients: univariate analysis.

                                                                     Good outcome (*n* = 35)    Poor outcome (*n* = 35)   *p*-Value
  ------------------------------------------------------------------ -------------------------- ------------------------- -----------
  Age, year                                                          54 (14--77), 35            56 (17--78), 35           0.1593
  Age \> 65                                                          8 (22.9%), 35              10 (28.6%), 35            0.7845
  Male                                                               25 (71.4%), 35             19 (54.3%), 35            0.2162
  Immunocompromised state                                            5 (14.3%), 35              12 (34.3%), 35            0.0944
  Duration prior to the hospital, day                                60 (7--365), 35            120 (9--1,090), 35        0.0224
  Hospital stay, day                                                 15 (3--55), 35             10 (4--116), 35           0.5215
  Cognition damage                                                   10 (28.6%), 35             7 (20.0%), 35             0.5772
  Mental and behavior disorder                                       10 (28.6%), 35             7 (20.0%), 35             0.5772
  Confusion                                                          2 (5.7%), 35               5 (14.3%), 35             0.4283
  Epilepsy                                                           9 (25.7%), 35              4 (11.4%), 35             0.2189
  Focal deficits                                                     12 (34.3%), 35             18 (51.4%), 35            0.2272
  Urinary incontinence/retention                                     1 (2.9%), 35               11 (31.4%), 35            0.0043
  Temperature upon admission, c                                      36.4 (35.9--39), 35        36.5 (36--38.7), 35       0.3327
  ICU admission                                                      2 (5.7%), 35               4 (11.4%), 35             0.6733
  Mechanical ventilation                                             1 (2.9%), 35               4 (11.4%), 35             0.3565
  Total tumors                                                       15 (42.9%), 35             24 (68.6%), 35            0.0542
  Immunotherapy                                                      19 (54.3%), 35             16 (45.7%), 35            0.4621
  Cerebrospinal fluid (CSF) WBC, ×10^6^/L                            4 (0--26), 21              8.5 (0--96), 22           0.1365
  CSF PRO, mg/L                                                      0.5 (0.2--3.9), 21         0.5 (0.3--1.5), 21        0.2627
  CSF Cl, mmol/L                                                     123.1 (106.4--132.8), 20   121.4 (107--128.3), 21    0.1588
  CSF Glu, mmol/L                                                    3.6 (3.2--8.6), 20         3.7 (2.5--5.2), 21        0.7345
  CSF IgG, mg/L                                                      38.1 (11.6--520), 18       64.4 (12--169), 17        0.0773
  IgG Index, ×1000                                                   503.7 (161.9--721.5), 11   636.2 (231.1--791.9), 6   0.2196
  Qalb, ×1000                                                        7.5 (2.6--70), 15          12.4 (2.2--63.8), 14      0.2172
  Neuron-specific endase, μg/L                                       12.4 (7--47.9), 22         14.4 (8.7--180.5), 25     0.1146
  AFP, ng/mL                                                         2.4 (0.6--10.3), 28        2.6 (0.9--8.5), 26        0.6841
  Carcinoembryonic antigen, μg/L                                     2.2 (0.5--8.1), 29         2.5 (0.5--13.1), 27       0.5550
  TGAB, IU/mL                                                        0.3 (0--175), 26           0.2 (0--38.7), 24         0.9530
  TPO, IU/mL                                                         0.7 (0.1--131), 26         0.6 (0.1--1,087), 24      0.8760
  Other autoantibodies                                               10 (52.6%), 19             8 (44.4%), 18             0.7460
  CK-MB, U/L                                                         10 (4--341), 19            11 (4--98), 25            0.4610
  AST/ALT, ×100                                                      121.7 (32.5--666.7), 35    105.9 (37--650), 35       0.9111
  BUN/Cr, ×100                                                       6.9 (1.8--14), 35          6.3 (3--14.5), 35         0.9906
  WBC, \>9.5×10^9^/L                                                 8 (22.9%), 35              10 (28.6%), 35            0.7845
  PMN, \>75%                                                         11 (31.4%), 35             13 (37.1%), 35            0.8012
  Platelet, \<125×10^9^/L                                            1 (2.9%), 35               2 (5.7%), 35              1
  Electroencephalogram                                               12 (70.6%), 17             9 (90.0%), 10             0.3630
  Electromyography                                                   15 (88.2%), 17             19 (90.5%), 21            1
  Magnetic resonance imaging FLAIR/T2 Abnormalities                  10 (33.3%), 30             8 (26.7%), 30             0.7782
  Computed tomography finding on tumor                               5 (18.5%), 27              8 (30.8%), 26             0.4734
  Paraneoplastic neurological disorders vs autoimmune encephalitis   14 (60.9%), 23             24 (82.8%), 29            0.1463

*Data presented as positive specimen (%) sample size, or median (range) sample size*.

Multivariate regression analysis was then performed for all patients. Urinary incontinence/retention (*p* = 0.0388) and an immunocompromised state (*p* = 0.0247) were significant factors associated with a poor outcome. Nevertheless, duration prior to the hospital was not statistically associated with a poor outcome (*p* = 0.0674) (Table [5](#T5){ref-type="table"}).

###### 

Poor outcome factors in onconeural antibody associated disorders patients: multivariate analysis.

                                      OR (95% CI)              *p*-Value
  ----------------------------------- ------------------------ -----------
  Urinary incontinence/retention      27.22 (1.51--1,137.04)   0.0388
  Immunocompromised state             34.6 (2.21--1,437)       0.0247
  Duration prior to the hospital, d   1.01 (1--1.03)           0.0674
  CSF Cl, mmol/L                      0.91 (0.71--1.11)        0.3555
  CSF IgG, mg/L                       1 (0.98--1.01)           0.8512
  CSF WBC, ×10^6^/L                   1.1 (1.02--1.3)          0.1846

*CSF = cerebrospinal fluid, OR = odds ratio*.

Discussion {#S4}
==========

In this study, we integrated PNDs and AE as a category named OAAD for the similarity of underlying pathogenesis and clinical management as follows. Most cases of OAAD are probably immune mediated, as demonstrated by the fact that anti-neuronal antibodies can be found in the CSF and serum ([@B4]). For paraneoplastic disorders, the ectopic expression of neuronal antigens within the tumor appears to contribute to breaking the immune tolerance and activating the immune response. For non-paraneoplastic disorders, molecular mimicry may initiate an immune response against neuronal antigens during the process of virus infection ([@B10]). The manifestation of OAAD can appear as encephalitis, encephalopathy, peripheral/autonomic neuropathy, or syndromes involving the neuromuscular junction. The clinical approach to diagnosing OAAD is to identify the neurological syndrome, detect specific antibodies in the serum or CSF, and verify the underlying cancer in some cases. In terms of clinical management, immunotherapy and tumor removal are the primary course of treatment.

Our study investigated the clinical presentation and management, CSF analysis, serum autoantibodies and tumor markers, the function of crucial organs, electrophysiology, and radiological findings in patients with OAAD. Furthermore, we used these data to identify potential predictors of outcome. In univariate analysis, duration prior to the hospital (*p* = 0.0224) and urinary incontinence/retention (*p* = 0.0043) were associated with a poor outcome. Furthermore, an immunocompromised state (*p* = 0.0944), the total number of tumors (*p* = 0.0542) and CSF IgG concentration (*p* = 0.0773) may also be associated with outcome. After multivariate regression analysis, urinary incontinence/retention and an immunocompromised state were shown to be significantly related to a poor outcome.

Urinary incontinence/retention is the main manifestation of damage to the autonomic nerve and its nerve center, including the lobulus paracentralis, hypothalamus, and parasympathetic center in the spinal cord. Our findings verified that this was the presentation of a serious injury to the nervous center and indicated a poor outcome. These results have not been reported previously for PNDs and AE. Further research is now required to explore the underlying pathogenesis of this condition. An immunocompromised state was confirmed as a factor associated with a poor outcome, as in a previous study of encephalitis ([@B11]). However, in the previous study of anti-NMDAR encephalitis, the predictors associated with a good outcome included early treatment, the lack of ICU requirement and a longer follow-up period ([@B12]), and therefore did not incorporate the factors utilized in the present study. More clinical research is now needed to identify the specific factors associated with outcome for patients with OAAD.

In terms of clinical presentation, we selected cognitive damage, mental and behavioral abnormality, confusion, epilepsy, focal deficits, urinary incontinence/retention, and temperature upon admission as influential factors with which to investigate outcome. Univariate and multivariate regression analysis confirmed that urinary incontinence/retention was a significant factor associated with poor outcome. Therapeutic measures, the total number of tumors and the duration prior to the hospital or during the hospital stay were also evaluated in the present study but did not show any significant relationship with outcome. Furthermore, ICU admission and mechanical ventilation did not show any relationship with outcome, which contradicted the results of a previous report ([@B12]). Univariate analysis showed that duration prior to the hospital was significantly associated with poor outcome (*p* = 0.0224), although this relationship was not significant when tested by multivariate regression analysis (*p* = 0.0674). In our cohort, duration prior to the hospital ranged from 1 week to 3 years. A longer time before the hospital visit always related to the progression of a potential tumor, the functional decline of major organs and a delay in the administration of appropriate treatments. This factor was verified as an indicator of poor outcome in the cohort study reported by Maarten ([@B12]).

In our CSF analysis, as well as investigating CSF components such as WBC, protein, Glu, and IgG, we also calculated the albumin quotient (Qalb) as a marker of the integrity of the blood--brain barrier, and IgG index as an estimate of intrathecal IgG synthesis (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Univariate analysis showed that only CSF IgG may be associated with a poor outcome, although there was no statistical significance when tested by multivariate regression analysis. High IgG index, pleocytosis and increased protein levels usually appear within the first few days after neurological symptoms ([@B4], [@B13]--[@B15]). The dynamic changes of CSF components may be one of the factors associated with the lack of statistical significance in our present study, as might the low numbers of CSF tested.

In the present study, we also investigated tumor markers, onconeural antibodies and coexistent anti-thyroid autoantibodies, anti-nuclear/myositis/ganglioside antibody profiles, and anti-MPO/PR3/AchR/AQP4 antibodies. Our testing showed that 16/47 patients (34%) were positive for tumor markers and NSE, and that the next highest positive marker was CEA (9/56 patients, 16.1%). There were 51/70 patients (72.9%) who possessed onconeural antibodies, including Hu (13 patients), NMDAR (13 patients), and Yo (11 patients) (see Table [1](#T1){ref-type="table"}). A total of 25 patients (35.7%) tested positive for serum autoantibodies. The coexistent autoantibody mainly included antithyroglobulin antibody (TGAb) (13 patients), anti-thyroid peroxidase antibody (TPOAb) (5 patients), ANA (5 patients). Neither univariate nor multivariate regression analysis revealed any significant relationship between antibody level and poor outcome. A previous study evaluated the coexistence of autoantibodies in cases of myasthenia gravis; 52% (39/75) patients tested positive for autoantibodies, including 27 cases with TPOAb, 17 cases with TGAb, and 17 cases of ANA ([@B16]). The pathogenesis underlying the coexistence of autoantibodies in the same patient remains unclear. Gene phenotypes, environmental factors, infection, immune dysfunction, and other factors may be connected with this phenomenon. The relationship between autoantibodies and the potential risks of autoimmune diseases, however, remains uncertain. Whether and how coexistent autoantibodies influence the therapeutic approaches and the prognosis of OAAD requires further research.

Clearly, the failure of crucial organs may be related to a poor outcome, at least to some extent. In the present study, we evaluated the function of important organs including heart, liver, kidney, and the hemopoiesis system. We tested AST/ALT, BUN/Cr, leukocytes, PMN, and thrombocytes in all patients, and CK-MB in 44 patients, in order to assess organic function. The number of patients with leukocytosis (WBC \> 9.5 × 10^9^/L) was 10 (28.6%) in the group of poor outcome and 8 (22.9%) in the group of good outcome; for patients with thrombocytopenia (Platelets \< 125 × 10^9^/L), the number was 1 (2.9%) and 2 (5.7%); for patients with PMN ratio rise (\>75%), the number was 11 (31.4%) and 13 (37.1%), respectively. Other indicators of organ function were rarely abnormal in our cohort. All results were analyzed by both univariate and multivariate regression analysis but none of these tests revealed a relationship with poor outcome. The function of the main organs is seldom evaluated as an indicator of outcome in a cohort study. While we obtained a negative result in this study, we plan to perfect the protocol and increase sample size in order to create a more robust study.

Our present study also considered electrophysiology and radiological findings in our diagnosis and in the prediction of outcome. The number of patients with abnormalities in EEG was 12 (70.6%) in the good outcome group and 9 (90%) in the poor outcome group; for patients with abnormalities in EMG, the number was 15 (88.2%) and 19 (90.5%); for MRI FLAIR/T2, the number was 10 (33.3%) and 8 (26.7%); for CT finding on tumor, the number was 5 (18.5%) and 8 (30.8%), respectively (Table [4](#T4){ref-type="table"}). The detailed data in the PNDs, AE, and possible OAAD groups are presented in Table [3](#T3){ref-type="table"}. Further statistical analysis failed to reveal any significant differences in terms of indicators of outcome. As reported previously, few patients with anti-NMDAR encephalitis showed FLAIR/T2 abnormalities in the cerebral parenchymal ([@B12]--[@B15]). In another study, abnormalities were observed in brain MRI and EEG in 33 and 90% of all patients, respectively ([@B12]), which concurred with our own cohort.

Overall, there was a 15.7% mortality rate (11/70 patients) in our current study, which was higher than the rates of 9.5 and 9% reported in previous studies ([@B11], [@B12]). The number of dead patients distributed in PNDs was 54.5% (6/11), in AE 18.2% (2/11), in possible OAAD 27.3% (3/11). In the PNDs group, 24 patients (63.2%, 24/38) had a poor outcome; this compared to 35.7% (5/14) and 33.3% (6/18) in the AE and possible OAAD groups. In terms of treatment, there were 35 patients who were administered with immunotherapy, predominantly steroids or IVIg, or both. Of the patients receiving treatments, 19 patients were classified as having a good outcome while 16 were classified as having a poor outcome; univariate analysis showed that there was no difference between these two groups of patients (*p* = 0.4621).

The present study strengthens our holistic evaluation of crucial organs and analyzes the coexistence of antoantibodies and tumor markers in patients with OAAD, while also considering clinical presentation and management, CSF analysis, electrophysiology, and radiological findings. The present study was limited in several ways. First, there was a shortage of exhaustive and complete data. Second, the study was retrospective in design, which led to the shortage of data. Finally, due to the long period of time before hospital attendance (mean: 146.4 days; range: 7--1090 days), the pathophysiological status of patients changed and appropriate treatments, including tumor surgery and immunotherapy, were delayed. Collectively, these factors would have influenced the clinical presentation, radiological findings, and test results, and may also have influenced the outcome, at least to some extent.

Conclusion {#S5}
==========

In the present study, 15.7% of our patients died and 50% of our patient cohort experienced a good or poor outcome, respectively. The distribution of mortality and outcome was not significantly different when compared across the PNDs, AE, and possible OAAD groups. In terms of indicators of prognosis, we identified that urinary incontinence/retention and an immunocompromised state represent significant factors that are associated with outcome (OR = 27.22 and 34.6, respectively) and portend a worse outcome.
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